Brian Fagan

Vice President Operations at Experic
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Doylestown, Pennsylvania, United States, US
Skills

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Experience

  • Experic
    • United States
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Vice President Operations
      • May 2021 - Present

    • Vice President, Client Services and Project Management
      • Sep 2019 - Apr 2021

    • Director, Supply Services
      • Jan 2018 - Sep 2019

  • Self-Employed
    • Real Estate
    • 1 - 100 Employee
    • Clinical Supplies Consultant
      • Jun 2016 - Dec 2017
  • AdiraMedica LLC
    • United States
    • Consumer Services
    • Director of Operations
      • Mar 2015 - Jun 2016
  • Shire
    • Japan
    • Biotechnology Research
    • 700 & Above Employee
    • Clinical Supplies Manager
      • Nov 2012 - Mar 2015

      Global Clinical Supply Chain Manager for SPD489 Major Depressive Disorder (MDD) program. Program Details: SPD489 is a controlled substance (CII) SPD489-209-Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in combination with an antidepressant in the treatment of adults with Major Depressive Disorder with inadequate response to prospective treatment with an antidepressant. Countries: United States, Argentina, Australia, Chile, United Kingdom SPD489-322-Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in combination with an antidepressant in the treatment of adults with Major Depressive Disorder with inadequate response to prospective treatment with an antidepressant. Countries: United States, Canada, Croatia, Mexico, Puerto Rico, Spain, SPD489-323-Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in combination with an antidepressant in the treatment of adults with Major Depressive Disorder with inadequate response to prospective treatment with an antidepressant. Countries: United States, Belgium, Czech Republic, Estonia, Finland, Germany, Hungary, Poland, Romania, South Africa, Sweden Show less

  • Fisher Clinical Services
    • United States
    • Pharmaceutical Manufacturing
    • 500 - 600 Employee
    • Manager, Client Services
      • 2009 - Nov 2012
  • Acculogix, LLC
    • Project Manager
      • 2005 - 2009
  • Cardinal Health PTS, LLC
    • Project Manager
      • 2002 - 2005
  • PCI Clinical Services
    • United States
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Production Supervisor
      • 2000 - 2001
  • PCI (Packaging Coordinators Inc)
    • Stability Packaging Coordinator/Supervisor
      • Sep 1998 - Apr 2000

    • Quality Control Inspector
      • Oct 1996 - Sep 1998

Community

You need to have a working account to view this content. Click here to join now